CD68 and breast cancer: In the group that received injections of the control oligonucleotide, we detected a 2.06-fold increase in Cd68 macrophage staining in BC sections (Figure 2b, p = 0.03) and a 2.4-fold increase in staining with the MOMA-2 antibody (Figure 2c, p = 0.02) in hyperglycemic mice (STZ-treated).